TOP TEN perturbations for 1555546_a_at (Homo sapiens)
Organism: Homo sapiens
Gene: 1555546_a_at
Selected probe(set): 209578_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 1555546_a_at (209578_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
ARC study 1 / untreated MCF-7 cell sample
Relative Expression (log2-ratio):1.8053331Number of Samples:2 / 2
| Experimental | ARC study 1 |
| MCF7 cells treated with 2uM ARC (4-amino-6-hydrazino-7-beta-d-ribofuranosyl-7H-pyrrolo-(2, 3-d)-pyrimidine-5-carboxamide, NSC 188491) for 24 hours. ATC code:--- | |
| Control | untreated MCF-7 cell sample |
| MCF-7 cells untreated. |
brefeldin A study 1 (0.5ug/ml; HCT 116) / tunicamycin study 2 (2ug/ml; HCT 116)
Relative Expression (log2-ratio):1.7308455Number of Samples:3 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116) |
| Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | tunicamycin study 2 (2ug/ml; HCT 116) |
| Human colon carcinoma cell line HCT116 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- |
bone cancer study 1 (PDX; chondrosarcoma, NOS; primary) / bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary)
Relative Expression (log2-ratio):1.7251339Number of Samples:2 / 2
| Experimental | bone cancer study 1 (PDX; chondrosarcoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondrosarcoma, NOS of the bone (subcutaneously implanted). | |
| Control | bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondroblastic osteosarcoma of the bone (subcutaneously implanted). |
hepatocyte (ESC) / HepaRG
Relative Expression (log2-ratio):1.7229614Number of Samples:8 / 12
| Experimental | hepatocyte (ESC) |
| Hepatocyte-like cells differentiated from embryonic stem cells (ESC) | |
| Control | HepaRG |
| Immortalized cancer cell line derived from female patient with hepatocellular carcinoma. Cells can be induced to differentiate into hepatocyte-like cells by exposure to DMSO. Synonyms:Hepa-RG Cellosaurus code: |
brefeldin A study 1 (0.5ug/ml; p53HCT116) / tunicamycin study 2 (2ug/ml; p53HCT116)
Relative Expression (log2-ratio):1.6960373Number of Samples:2 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; p53HCT116) |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | tunicamycin study 2 (2ug/ml; p53HCT116) |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- |
colorectal cancer study 43 (metastase; brain) / colorectal cancer study 43 (metastase; lung)
Relative Expression (log2-ratio):1.6896276Number of Samples:2 / 5
| Experimental | colorectal cancer study 43 (metastase; brain) |
| Metastatic tumor tissue obtained from the brain of patients with primary colorectal adenocarcinoma. | |
| Control | colorectal cancer study 43 (metastase; lung) |
| Metastatic tumor tissue obtained from the lung of patients with primary colon adenocarcinoma. |
colorectal cancer study 43 (metastase; brain) / colorectal cancer study 43 (metastase; liver)
Relative Expression (log2-ratio):1.6542168Number of Samples:2 / 25
| Experimental | colorectal cancer study 43 (metastase; brain) |
| Metastatic tumor tissue obtained from the brain of patients with primary colorectal adenocarcinoma. | |
| Control | colorectal cancer study 43 (metastase; liver) |
| Metastatic tumor tissue obtained from the liver of patients with primary colon adenocarcinoma. |
myotonic dystrophy study 4 (skeletal muscle; DM2) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-1.6420908Number of Samples:8 / 3
| Experimental | myotonic dystrophy study 4 (skeletal muscle; DM2) |
| Unspecified skeletal muscle biopsies obtained from patients with myotonic dystrophy type 2 (DM2). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
myotonic dystrophy study 4 (biceps brachii; DM1) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-1.6305141Number of Samples:3 / 3
| Experimental | myotonic dystrophy study 4 (biceps brachii; DM1) |
| Biceps brachii biopsies obtained from patients with myotonic dystrophy type 1 (DM1). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |
myotonic dystrophy study 4 (deltoid muscle; DM-like) / normal skeletal muscle tisuue (fetal)
Relative Expression (log2-ratio):-1.6185884Number of Samples:3 / 3
| Experimental | myotonic dystrophy study 4 (deltoid muscle; DM-like) |
| Deltoid muscle biopsies obtained from patients with myotonic-like dystrophy (DMx; DM-like; no DMPK or ZNF9 expansion). | |
| Control | normal skeletal muscle tisuue (fetal) |
| Commercially purchased normal fetal skeletal muscle tissue samples. |